Temocillin (6-methoxy-ticarcillin) is a beta-lactam antibiotic with exceptional resistance to
most beta-lactamases. In this context, it is now increasingly used as carbapenem-sparing
antibiotic in patients with suspected infection by Enterobactreriaceae suspected to produce
extended-spectrum beta-lactamases. Little is known about dosing and elimination of temocillin
in children. While available literature of temocillin use in paediatrics refers mainly to its
clinical efficacy in the treatment of urinary tract infections, the drug is also used for the
treatment of suspicion of cholangitis in cirrhotic paediatric patients, and as antibiotic
prophylaxis following an hepatic transplant in children (both off-label indications). There
is, therefore, a pressing need to explore the pharmacokinetics and pharmacodynamics of
temocillin in the paediatric population, in order to provide clear guidance on an appropriate
dosing regimen. The study objectives are: (1) characterisation of the pharmacokinetics (PK)
of temocillin in 3 paediatric populations, (2) proposal and development of a dosing schedule
that can ensure therapeutic concentrations (40% ƒT > MIC) and optimize treatment chances of
success, and (3) characterization of MICs of microbiological strains (when available) to
temocillin.